Femara’s Pink Ribbon Logo Raises Red Flag With FDA
This article was originally published in The Pink Sheet Daily
The agency says the incorporation of a pink “breast cancer ribbon” into the “F” in Novartis’ letrozole proprietary name might confuse users.
You may also be interested in...
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.